3/10
12:06 pm
tara
Protara Therapeutics (TARA) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Protara Therapeutics (TARA) had its "buy" rating reaffirmed by TD Cowen.
3/10
08:32 am
tara
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
Low
Report
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
3/10
08:00 am
tara
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Low
Report
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
3/4
08:00 am
tara
Protara Therapeutics (TARA) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $27.00 price target on the stock.
Medium
Report
Protara Therapeutics (TARA) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $27.00 price target on the stock.
3/1
08:52 pm
tara
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]
Low
Report
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]
2/23
05:05 pm
tara
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
High
Report
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2/19
08:27 am
tara
Protara Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Protara Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/19
08:00 am
tara
Protara Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Protara Therapeutics to Participate in Upcoming Investor Conferences
2/10
08:05 am
tara
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Low
Report
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
2/2
04:05 pm
tara
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/22
08:00 am
tara
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
Low
Report
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium